DOI QR코드

DOI QR Code

N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population

  • Lee, Kyung-Hoon (Division of Cardiology, Gachon University of Medicine and Science, Gil Medical Center) ;
  • Kim, Jang-Young (Department of Cardiology, Wonju College of Medicine, Yonsei University) ;
  • Koh, Sang-Baek (Department of Preventive Medicine,Wonju College of Medicine, Yonsei University) ;
  • Lee, Seung-Hwan (Department of Cardiology, Wonju College of Medicine, Yonsei University) ;
  • Yoon, Jung-Han (Department of Cardiology, Wonju College of Medicine, Yonsei University) ;
  • Han, Sang-Woo (Department of Cardiology, Wonju College of Medicine, Yonsei University) ;
  • Park, Jong-Ku (Department of Preventive Medicine,Wonju College of Medicine, Yonsei University) ;
  • Choe, Kyung-Hoon (Department of Cardiology, Wonju College of Medicine, Yonsei University) ;
  • Yoo, Byung-Su (Department of Cardiology, Wonju College of Medicine, Yonsei University)
  • Received : 2010.03.29
  • Accepted : 2010.05.26
  • Published : 2010.12.30

Abstract

Background and Objectives: B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels may serve as a useful marker of cardiovascular risk for screening of the general population. We evaluated reference levels and distribution of NT-proBNP in the Korean general population based on a large cohort study. Subjects and Methods: We included 1,518 adult subjects (ages 40-69) of a community-based cohort from the Korea Rural Genomic Cohort (KRGC) Study. Thorough biochemical and clinical data were recorded for all subjects. Levels of NT-proBNP from all participants were determined. In order to determine normal reference levels, subjects with factors known to influence NT-proBNP levels were excluded. Results: The characteristics of the cohort are described below; subjects were 41.2% male, and the mean age was 54.8${\pm}$8.4 years. The distribution of risk factors for cardiovascular disease in the cohort included hypertension (25%), left ventricular hypertrophy by electrocardiography (ECG-LVH) (15%), hypercholestolemia (4.5%), smoking (32%), diabetes (10.9%), history of coronary heart disease (4.9%), history of heart failure (0.9%), symptoms of heart failure (6.1%), elevated serum creatinine (${\geq}$1.5, 3.7%), and severe obesity (body mass index >30 kg/m$^2$, 4.6%). The levels of NT-proBNP of all subjects are shown below; the mean was 60.1${\pm}$42.1, and the median was 36.5 pg/mL. In addition, the levels of NT-proBNP of normal subjects (which did not have any risk factors, n=224) are shown below; the mean was 40.8, and the median was 32.1 pg/mL. In normal subjects, the NTproBNP level was slightly higher in females (25.7${\pm}$24.8 vs. 46.9${\pm}$35.4, p<0.001). NT-proBNP level increased with age in both the normal population and the total population. There were no significant differences in NT-proBNP levels in subjects who smoked, or had diabetes mellitus, hypertension or ECG-LVH. However, in subjects with a history of congestive heart failure (CHF) (58.5${\pm}$103.29 vs. 213.8${\pm}$258.8, p<0.005), elevated serum creatinine levels (${\geq}$1.5 mg/dL, 146.2${\pm}$98.2 vs. 54.3${\pm}$38.1, p<0.001), or who were older (${\geq}$60, 48.4 vs. 84.2${\pm}$139.5 pg/mL, p<0.05), the BNP level was higher. In addition, patients with more than 3 risk factors for CHF had higher BNP levels (risk 0: 40.8${\pm}$34.0, 1-2: 57.4${\pm}$93.2, ${\geq}$3: 85.0${\pm}$152.9 pg/mL). NT-proBNP levels were also related with age, sex, urine albumin, serum Cr, and high sensitivity C-reactive protein (p<0.05). Conclusion: We determined the reference value and distribution of NT-proBNP in the Korean adult general population. We also found that adjustments for the independent effects of age, sex and renal function appear necessary when determining cardiac risk based on proBNP levels.

Keywords

References

  1. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16. https://doi.org/10.1161/01.CIR.96.2.509
  2. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53. https://doi.org/10.1016/S0140-6736(97)06031-5
  3. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardiol 2001;37:379-85. https://doi.org/10.1016/S0735-1097(00)01156-6
  4. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. https://doi.org/10.1056/NEJMoa020233
  5. Yoo BS, Kim WJ, Jung HS, et al. The clinical experiences of B-type natriuretic peptide blood concentrations for diagnosis in congestive heart failure: the single hospital experience based on the large clinical database. Korean Circ J 2004;34:684-92. https://doi.org/10.4070/kcj.2004.34.7.684
  6. Sutton TM, Stewart RA, Gerber IL, et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;41:2280-7. https://doi.org/10.1016/S0735-1097(03)00486-8
  7. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34. https://doi.org/10.1016/0002-9343(92)90011-Y
  8. Rossi A, Enriquez-Sarano M, Burnett JC Jr, Lerman A, Abel MD, Seward JB. Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000;35:1256-62. https://doi.org/10.1016/S0735-1097(00)00515-5
  9. Choe HM, Yoo BS, Ryu HY, et al. The early changing pattern of the Btype natriuretic peptide concentration and its significance as a prognostic marker after acute myocardial infarction. Korean Circ J 2006;36: 526-34. https://doi.org/10.4070/kcj.2006.36.7.526
  10. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655-63. https://doi.org/10.1056/NEJMoa031994
  11. Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002;87:131-5. https://doi.org/10.1136/heart.87.2.131
  12. McDonagh TA, McDonald K, Maisel AS. Screening for asymptomatic left ventricular dysfunction using B-type natriuretic Peptide. Congest Heart Fail 2008;14(4 Suppl):5-8. https://doi.org/10.1111/j.1751-7133.2008.08283.x
  13. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82. https://doi.org/10.1016/S0735-1097(02)02059-4
  14. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594-600. https://doi.org/10.1161/01.CIR.0000112582.16683.EA
  15. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003;108:13-6. https://doi.org/10.1161/01.CIR.0000081657.83724.A7
  16. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51. https://doi.org/10.1136/heart.89.7.745
  17. Segawa T, Nakamura M, Itai K, Onoda T, Okayama A, Hiramori K. Plasma B-type natriuretic peptide levels and risk factors for congestive heart failure in a Japanese general population. Int Heart J 2005;46: 465-75. https://doi.org/10.1536/ihj.46.465
  18. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101:9-15.
  19. Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of aminoterminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006;12:452-7. https://doi.org/10.1016/j.cardfail.2006.04.005
  20. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-Btype natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008;101:29-38. https://doi.org/10.1016/j.amjcard.2007.11.017
  21. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide?: how well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76. https://doi.org/10.1093/eurheartj/ehi410
  22. Marz W, Tiran B, Seelhorst U, et al. N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2007;53:1075-83. https://doi.org/10.1373/clinchem.2006.075929
  23. Magnusson M, Melander O, Israelsson B, Grubb A, Groop L, Jovinge S. Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 2004;27:1929-35. https://doi.org/10.2337/diacare.27.8.1929
  24. Hildebrandt P, Richards AM. Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol 2008;101:21-4.
  25. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:3004-10. https://doi.org/10.1093/eurheartj/ehl406
  26. Bruch C, Fischer C, Sindermann J, Stypmann J, Breithardt G, Gradaus R. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 2008;102:469-74. https://doi.org/10.1016/j.amjcard.2008.03.082
  27. Wang HS, Yoo BS, Chung IY, et al. Is B-type natriuretic peptide (BNP) measurement useful test for diagnosing systolic heart failure in patients with moderate to severe renal insufficiency? Korean Circ J 2005;35: 897-903. https://doi.org/10.4070/kcj.2005.35.12.897
  28. Almirez R, Protter AA. Clearance of human brain natriuretic peptide in rabbits: effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 1999;289:976-80.
  29. Coste J, Jourdain P, Pouchot J. A gray zone assigned to inconclusive results of quantitative diagnostic tests: application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. Clin Chem 2006;52:2229-35. https://doi.org/10.1373/clinchem.2006.072280
  30. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. Intern Med J 2008;38:101-13. https://doi.org/10.1111/j.1445-5994.2007.01454.x
  31. Austin MJ, Heneghan MA. Multiple biomarkers and cardiovascular risk. N Engl J Med 2008;359:760-1. https://doi.org/10.1056/NEJMc081303
  32. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Longterm stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004;42:942-4.

Cited by

  1. Renal dysfunction as a risk factor for painless myocardial infarction: results from Korea Acute Myocardial Infarction Registry vol.101, pp.10, 2010, https://doi.org/10.1007/s00392-012-0461-1
  2. The need for multicentre cardiovascular clinical trials in Asia vol.10, pp.6, 2010, https://doi.org/10.1038/nrcardio.2013.49